Patents by Inventor Kevin J. Tracey

Kevin J. Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090324588
    Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.
    Type: Application
    Filed: November 15, 2006
    Publication date: December 31, 2009
    Applicant: The Feinstein Institute for Medical Research
    Inventors: Lihong Yang, Kevin J. Tracey
  • Publication number: 20090275997
    Abstract: Described herein are systems, method and devices for modulating the cholinergic anti-inflammatory pathway. The systems described herein may include one or more implantable leads configured to be used to stimulate the inflammatory reflex. These leads typically include a flexible body region, a plurality of electrodes (or contacts) and may be used with a stylet or other inserter. The leads may also include one or more anchors. Exemplary leads may be intra-carotid sheath field-effect leads (“sheath FE” leads), carotid sheath cuff leads (“sheath cuff” leads), intracardiac leads, vagus nerve cuff leads (“vagus cuff” leads), and intravenous leads (“intravascular” leads). Leads (e.g., intravascular leads) may be chronic or acute.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 5, 2009
    Inventors: Michael Allen Faltys, James W. Broderick, Kevin J. Tracey
  • Publication number: 20090263916
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG 1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: April 13, 2009
    Publication date: October 22, 2009
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20090247934
    Abstract: Described herein are devices, systems and method of treating inflammation, including methods of treating a T-cell mediated disease. In particular, described herein are methods of treating inflammation including the steps of stimulating a subject's inflammatory reflex to inhibit the immune response and administering a T-cell modifying agent to modify the activity of splenic T-cells. Also described herein are systems for treating inflammation including an inflammatory reflex stimulation module and a T-cell response modifying module. The T-cell response modifying module typically modifies the response of splenic T-cells to enhance or otherwise regulate the effect of stimulation of the inflammatory reflex.
    Type: Application
    Filed: March 31, 2009
    Publication date: October 1, 2009
    Inventors: Kevin J. Tracey, Mauricio Rosas-Ballina
  • Publication number: 20090248097
    Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
    Type: Application
    Filed: April 24, 2008
    Publication date: October 1, 2009
    Applicant: Feinstein Institute for Medical Research, The
    Inventors: Kevin J. Tracey, Jared M. Huston
  • Patent number: 7572446
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 11, 2009
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20090143831
    Abstract: Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: October 27, 2008
    Publication date: June 4, 2009
    Inventors: Jared M. Huston, Kevin J. Tracey
  • Patent number: 7537908
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: May 26, 2009
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20090123456
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.
    Type: Application
    Filed: March 15, 2007
    Publication date: May 14, 2009
    Inventors: Kevin J. Tracey, Hong Wang
  • Publication number: 20090062874
    Abstract: Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.
    Type: Application
    Filed: August 26, 2008
    Publication date: March 5, 2009
    Inventors: Kevin J. Tracey, Howland Shaw Warren, Christine N. Metz
  • Publication number: 20080249439
    Abstract: Described herein are devices, systems and method for treating inflammatory disorders by modulating a subject's inflammatory reflex. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject in a manner which significantly reduces proinflammatory cytokines in the subject and/or provides a therapeutically effective treatment for the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.
    Type: Application
    Filed: March 13, 2008
    Publication date: October 9, 2008
    Applicant: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys
  • Publication number: 20080214454
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: September 19, 2007
    Publication date: September 4, 2008
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
  • Publication number: 20080167234
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: September 19, 2007
    Publication date: July 10, 2008
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Mitchell P. Fink
  • Publication number: 20080140138
    Abstract: Methods for inhibiting pro-inflammatory cytokine release or inflammation in a vertebrate are provided. The methods comprise activating a brain muscarinic receptor of the vertebrate, or directly stimulating a vagus nerve pathway in the brain of the vertebrate. Also provided are methods for conditioning a vertebrate to inhibit the release of a pro-inflammatory cytokine or reduce inflammation in the vertebrate upon experiencing a sensory stimulus. The methods comprise (a) activating a muscarinic brain receptor or directly stimulating the vagus nerve pathway in the brain of the vertebrate and providing the sensory stimulus to the vertebrate within a time period sufficient to create an association between the stimulus and the activation of the brain muscarinic receptor; and (b) repeating step (a) at sufficient time intervals and duration to reinforce the association sufficiently for the inflammation to be reduced by the sensory stimulus alone.
    Type: Application
    Filed: May 29, 2007
    Publication date: June 12, 2008
    Inventors: Svetlana M. Ivanova, Kevin J. Tracey
  • Patent number: 7329643
    Abstract: Methods of inhibiting HMGB1 release by a mammalian cell are provided. The methods comprise treating the cell with sufficient fetuin to inhibit HMGB1 release. Methods of inhibiting an inflammatory cytokine cascade in a mammal are also provided. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal. Also provided are methods of treating a condition in a mammal characterized by an inflammatory cytokine cascade. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: February 12, 2008
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haicho Wang, Andrew E. Sama
  • Patent number: 7304034
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: December 4, 2007
    Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
  • Patent number: 7273872
    Abstract: Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: September 25, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Hong Wang
  • Patent number: 7238715
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: July 3, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Hong Wang
  • Patent number: 7220723
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent that inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: May 22, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Huan Yang
  • Patent number: 7192917
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: March 20, 2007
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang